Should You Buy Alkermes plc Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Alkermes plc (ALKS) is rated as a strong fundamental performer with a QOC score of 8.6/10. Trading at $48.90, our valuation engine evaluates whether the market price reflects the company's underlying earnings power.
The short answer: 2 of 10 CirclFi valuation models project upside for Alkermes plc (ALKS) at $48.90 — the model consensus leans bearish, with a Quality Score of 8.6/10 and Value-Trap risk of 12/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Alkermes plc (ALKS) in 2026?
What Is the Bull Case vs the Bear Case for Alkermes plc (ALKS)?
| Bull case — $64.90 target (+32.7%) | Bear case — $5.67 target (-88.4%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, Alkermes plc's quality score of 8.6/10 demonstrates the operational excellence that historically correlates with long-term shareholder value creation. | According to the CirclFi Deep Alpha Valuation Engine, the Earnings Power Value (EPV) model sees the stock as overvalued with a fair value of $5.67 (-88.4%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the Bayesian DCF model targets a fair value of $64.90 (+32.7%), anchoring the bull case with a methodology that incorporates probability-weighted cash flow scenarios. | According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +121.1% spread between the most bullish and bearish models, signaling elevated analytical uncertainty. |
| Industry tailwind: orphan drug designation could provide meaningful support for Alkermes plc's revenue and margin trajectory in the Drug Manufacturers - Specialty & Generic space. | Industry headwind: patent expiration revenue loss represents a meaningful risk for Alkermes plc and its Drug Manufacturers - Specialty & Generic peers. |
How Does ALKS Compare to Its Drug Manufacturers - Specialty & Generic Peers?
Valuation data pages: PAHC · HLN · COLL · ETST · RDY · BCRX · AKBA · RMTI · KOAN · UTHR · AMPH
See full Drug Manufacturers - Specialty & Generic rankings →
Which Other Stocks Score Like ALKS on Quality?
Closest companies to ALKS’s Quality of Company score of 8.6/10, across all industries.
- EXPO — Exponent, Inc. (QOC 8.6) · analysis
- GTM — ZoomInfo Technologies Inc. (QOC 8.6) · analysis
- HOMB — Home BancShares, Inc. (QOC 8.6) · analysis
- PCB — PCB Bancorp (QOC 8.6) · analysis
- RSG — Republic Services, Inc. (QOC 8.6) · analysis
- BCO — The Brink's Company (QOC 8.6) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Drug Manufacturers - Specialty & Generic Screens Does ALKS Appear In?
So Is Alkermes plc (ALKS) Worth Buying in 2026?
Our valuation engine sends a clear cautionary signal on Alkermes plc at $48.90. 8/10 models flag overvaluation, median fair value sits at $28.52 (-41.7%), and the risk-reward profile appears unfavorable. Quality at 8.6/10 is the one bright spot, but premium quality at the wrong price can still destroy returns. This is a stock where patience — or avoidance — may be the optimal strategy.
These are quantitative model outputs, not investment recommendations. Alkermes plc's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About ALKS Stock?
Should I buy ALKS stock right now?
Based on CirclFi's multi-model analysis, 2 of 10 models see upside for ALKS at $48.90. The models are divided, which means the investment case depends heavily on your assumptions about Alkermes plc's future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Alkermes plc?
Key risks include: wide model disagreement (1044% spread), signaling high uncertainty; general market and sector-specific risks affecting Drug Manufacturers - Specialty & Generic companies. Always diversify and consult a financial advisor.
How does ALKS compare to its competitors?
Among Drug Manufacturers - Specialty & Generic peers, ALKS holds a Quality Score of 8.6/10. Comparable companies include PAHC (QOC 8.7), HLN (QOC 8.5), COLL (QOC 8.8). The relative ranking helps investors identify whether ALKS offers better fundamental quality than alternatives in the same sector.
Is ALKS a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. ALKS's Quality Score of 8.6/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy ALKS at?
CirclFi does not provide target buy prices or price alerts. However, our 10 active models produce fair value estimates ranging from $5.67 to $64.90. At $48.90, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for ALKS.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad